Work

Aprepitant (AP) For Prevention Of Nausea And Vomiting Secondary To High-Dose Cyclophosphamide (Cy) Administered To Patients Undergoing Autologous (A) Peripheral Blood Progenitor Cell (Pbpc) Mobilization: Final Results Of A Phase Ii Trial

Year: 2010

Type: article

Abstract: AP is a neurokinin-1 receptor antagonist with unique antiemetic activity. We conducted a phase II trial evaluating efficacy & safety of AP in combination with 5-HT3 antagonists & adjusted dose of dexamethasone (D) in pts receiving high-dose CY for stem cell mobilization. High-dose CY is associated with significant nausea & vomiting. CY and filgrastim provides a better PBPC yield as compared to filgrastim (failure rate15-20%). Primary endpoint was the control of vomiting without the use of rescue anti-emetics at 24hours after high dose CY.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2009.12.140